REGiMMUNE Initiates Phase I/II Clinical Trial for GvHD
January 31, 2012 19:21 ET
|
REGiMMUNE
TOKYO--(Marketwire - Jan 31, 2012) - REGiMMUNE Corporation said today that it has begun a Phase I/II study of its proprietary compound RGI-2001 for Graft versus Host Disease (GvHD) associated with...
REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress
May 04, 2010 17:15 ET
|
REGiMMUNE
SAN DIEGO, CA--(Marketwire - May 4, 2010) - REGiMMUNE Corporation said today that data from a preclinical study showed enhanced immune suppression when ToleroVax (RGI-2001), its lead product...
REGiMMUNE to Present Data From Preclinical Study of RGI-2001 at the 2010 American Transplant Congress
April 28, 2010 08:00 ET
|
REGiMMUNE
MOUNTAIN VIEW, CA--(Marketwire - April 28, 2010) - REGiMMUNE Corporation will present new preclinical data of the company's lead product, RGI-2001 (ToleroVax), at the 2010 American Transplant...
Astellas and REGiMMUNE to Collaborate on New Vaccine Technology
July 22, 2009 03:00 ET
|
REGiMMUNE
TOKYO and MOUNTAIN VIEW, CA--(Marketwire - July 22, 2009) - REGiMMUNE Corporation today
announced that Astellas Pharma Inc. and REGiMMUNE have entered into a
collaboration agreement to jointly...
REGiMMUNE Presents Enhanced Efficacy Data in Preclinical Transplantation Models at the 2009 American Transplant Congress
June 01, 2009 08:00 ET
|
REGiMMUNE
BOSTON, MA--(Marketwire - June 1, 2009) - REGiMMUNE Corporation today announced that its
lead product candidate RGI-2001, in combination with a low-dose of
Sirolimus, demonstrated enhanced efficacy...
REGiMMUNE to Present at the 2009 American Transplant Congress
May 12, 2009 07:58 ET
|
REGiMMUNE
MOUNTAIN VIEW, CA--(Marketwire - May 12, 2009) - REGiMMUNE Corporation today announced
that a company abstract has been accepted for presentation at the 2009
American Transplant Congress (ATC, May 30...
REGiMMUNE Receives $12 Million in Grants to Develop Transplant and Allergy Drugs
December 08, 2008 08:00 ET
|
REGiMMUNE
MOUNTAIN VIEW, CA and TOKYO--(Marketwire - December 8, 2008) - REGiMMUNE Corporation, a
privately held biopharmaceutical company focused on developing technologies
and products for immune disorders,...
REGiMMUNE Raises $8,000,000 in Series B Financing
May 06, 2008 08:00 ET
|
REGiMMUNE
MOUNTAIN VIEW, CA and TOKYO--(Marketwire - May 6, 2008) - REGiMMUNE Corporation, a
privately held biopharmaceutical company, announced today that it has
closed its Series B financing for a total of...
REGiMMUNE Receives Grant Award From METI
August 08, 2007 08:00 ET
|
REGiMMUNE
MOUNTAIN VIEW, CA and TOKYO, JAPAN--(Marketwire - August 8, 2007) - REGiMMUNE Corporation, a
privately held biopharmaceutical company, announced today it has been
awarded a grant from the Japanese...
REGiMMUNE Announces Appointment of Shirley Clayton to Board of Directors
February 21, 2007 08:30 ET
|
REGiMMUNE
MOUNTAIN VIEW, CA and TOKYO -- (MARKET WIRE) -- February 21, 2007 -- REGiMMUNE Corporation., a
privately held biopharmaceutical company, announced today the appointment
of Shirley Liu Clayton as a...